Furthermore, it was demonstrated that the outcomes of all-cause mortality, relapse, and end-stage renal disease were similar between ACPA-positive and negative patients, suggesting that the clinical value of this antibody may be relatively limited. This evidence concerns the gene PRTN3 and stage 5 chronic kidney disease.